Skip to main content

Table 6 Effect of duration of treatment with aspirin on the risk of UGIB and perforation among current users as compared to non-use

From: Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

  All cases Controls Adjusted RR*
  (N=2,105) (N=11,500) (95%CI)
Days of treatment    
(consecutive prescriptions)    
   1-60 (all users) 40 52 4.5 (2.9-7.1)
First-ever users 25 32 4.6 (2.7-8.1)
Distant users 15 20 4.2 (2.0-8.6)
   61-180 34 71 2.7 (1.7-4.2)
   181-730 96 286 1.9 (1.5-2.5)
   >730 117 428 1.6 (1.3-2.0)
  1. *Adjusted for sex, age, calendar year, antecedents of gastrointestinal disorders, smoking status, alcohol consumption and use of NSAIDs, anticoagulants, steroids, SSRIs and paracetamol. Additional adjustment for antiulcer drugs use did not change the estimates.